Pursuing the curative blueprint for early myeloma. - Wikidata - awgldk - TriplyDB

Pursuing the curative blueprint for early myeloma.

Pursuing the curative blueprint for early myeloma.

http://www.wikidata.org/entity/Q37046979

about

Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma Curing myeloma at last: defining criteria and providing the evidence.Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials.The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies.Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

P2860

Q27027729-D0905B64-DF2D-4B4C-B4A7-48204C029ADB Q34508313-7278ACEE-A19A-4C88-AD9C-DDC0D090A728 Q38756800-93974ADE-A247-42FA-8CBD-750C0D142CF5 Q41557109-7ACAAC32-F69B-4458-BB87-F029C195CA89 Q43057946-B2B96869-412B-447B-94D3-E8C08113A9EF Q47833870-D1626A53-4B85-47FC-BFFC-ED5BDFBF2E6A Q52727038-736AB17A-7AF2-4F52-83EC-C67A044B89E1 Q56461029-C329D8C5-A4DC-4A21-855E-8DCFF545ACA6

P2860

Pursuing the curative blueprint for early myeloma.

http://www.wikidata.org/entity/Q37046979

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pursuing the curative blueprint for early myeloma.

@en

Pursuing the curative blueprint for early myeloma.

@nl

type

label

Pursuing the curative blueprint for early myeloma.

@en

Pursuing the curative blueprint for early myeloma.

@nl

prefLabel

Pursuing the curative blueprint for early myeloma.

@en

Pursuing the curative blueprint for early myeloma.

@nl

P1433

Q37046979-80926CB1-6853-4CB6-A94E-F010BBBB69AB

P1476

Q37046979-35D52406-9161-4D94-B2D9-5DFAF74F3FC2

P2093

Q37046979-7A527A74-655B-47F9-B3C8-9DCAD18CFCA0

Q37046979-87DEC38A-833E-49AB-977C-4A4DAB679A0E

Q37046979-BD8309DA-646C-4C68-97F3-8C169E6DEE01

P2860

Q37046979-039C9648-F8FF-45BD-8590-E1B8B9AF535A

Q37046979-047788CB-3DD2-442A-BAD7-A378E5792F5C

Q37046979-0E09A932-35AC-4E22-9122-AC0EF842C057

Q37046979-3872BDDA-007D-4A8A-AE87-AD3F3BAB3C29

Q37046979-4110B5F3-6E92-4AB3-87D3-EF3EFBEF6D9C

Q37046979-4EC1EB28-C349-4C9E-AACC-EDB9816EE163

Q37046979-63242D33-0C40-40DF-BF1E-A058F9FEEEE9

Q37046979-638C2B30-FA0C-4C02-926D-2594FC3A0CBD

Q37046979-706D8E1F-852C-40F6-8EB1-48DF28E5214E

Q37046979-7C708A8F-1323-4CCE-AE25-E3890E739E2C

P304

Q37046979-B0004E31-DE92-4219-8C5E-DADDADE8102F

P31

Q37046979-4913A292-2CA6-4A7F-B9E1-86A82DDE1B1C

P356

Q37046979-CD23C5E9-C4E0-4575-9319-73B6C0465B95

P407

Q37046979-0D5960D6-1C81-4267-B7B2-E59A1D26AF9D

P433

Q37046979-ADC6C4A1-B398-46BD-984C-8773A647A01D

P478

Q37046979-BA069108-C0D0-4F19-A417-5A1F6D0C6F0D

P50

Q37046979-7730004E-DB02-4099-9146-C6BFA950792C

P577

Q37046979-F59F5C3F-7091-4883-8EDA-7A00A8884ED4

P5875

Q37046979-AF891A6A-75C9-4623-88B5-E0BD3BDD2070

P698

Q37046979-E0F59263-14E5-4B7C-BE1B-65D56C8644E9

P932

Q37046979-0EE29649-62F8-4448-A15E-B08BD56F5A8A

P356

BLOOD-2013-01-481291

P1433

P1476

Pursuing the curative blueprint for early myeloma.

@en

P2093

Mark Roschewski

http://www.w3.org/2001/XMLSchema#string

Neha Korde

http://www.w3.org/2001/XMLSchema#string

S Peter Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

The clonal evolution of tumor cell populations

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Approach to the treatment of multiple myeloma: a clash of philosophies.

Myeloma as a model for the process of metastasis: implications for therapy

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

P304

486-490

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-01-481291

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

239941637

http://www.w3.org/2001/XMLSchema#string

P698

23782936

http://www.w3.org/2001/XMLSchema#string

P932

3724188

http://www.w3.org/2001/XMLSchema#string